{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:24:30Z","timestamp":1788279870123,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hypertension is associated with impaired glucose tolerance and insulin resistance. Medical treatment that interferes with various steps in the renin-angiotensin system improves glucose tolerance and insulin resistance. However, it remains unclear if long-acting calcium channel blockers (CCBs) such as azelnidipine and amlodipine affect glucose tolerance and insulin resistance in clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Seventeen non-diabetic patients with essential hypertension who had controlled blood pressure levels using amlodipine (5 mg\/day) were enrolled in this study. After randomization, either azelnidipine (16 mg\/day) or amlodipine (5 mg\/day) was administered in a crossover design for 12-weeks. At baseline and the end of each CCB therapy, samples of blood and urine were collected and 75 g oral glucose tolerance test (OGTT) was performed. In addition, hematopoietic progenitor cells (HPCs) were measured at each point by flow cytometry and endothelial functions were measured by fingertip pulse amplitude tonometry using EndoPAT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Although blood pressure levels were identical after each CCB treatment, the heart rate significantly decreased after azelnidipine administration than that after amlodipine administration (<jats:italic>P<\/jats:italic> &lt; 0.005). Compared with amlodipine administration, azelnidipine significantly decreased levels of glucose and insulin 120 min after the 75 g OGTT (both <jats:italic>P<\/jats:italic> &lt; 0.05). Serum levels of high-sensitivity C-reactive protein (<jats:italic>P<\/jats:italic> = 0.067) and interleukin-6 (<jats:italic>P<\/jats:italic> = 0.035) were decreased. Although endothelial functions were not different between the two medication groups, the number of circulating HPCs was significantly increased after azelnidipine administration (<jats:italic>P<\/jats:italic> = 0.016).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These results suggest that azelnidipine treatment may have beneficial effects on glucose tolerance, insulin sensitivity, the inflammatory state, and number of circulating progenitor cells in non-diabetic patients with essential hypertension.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1475-2840-10-79","type":"journal-article","created":{"date-parts":[[2011,9,10]],"date-time":"2011-09-10T18:14:31Z","timestamp":1315678471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between Azelnidipine and amlodipine on Glucose tolerance and ENdothelial function - a crossover Trial (AGENT)"],"prefix":"10.1186","volume":"10","author":[{"given":"Kosuke","family":"Fukao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kiyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsumi","family":"Kume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Ohsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Matsumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,10]]},"reference":[{"issue":"7533","key":"388_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","volume":"332","author":"R Huxley","year":"2006","unstructured":"Huxley R, Barzi F, Woodward M: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006, 332 (7533): 73-78. 10.1136\/bmj.38678.389583.7C.","journal-title":"BMJ"},{"issue":"12","key":"388_CR2","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.2337\/diacare.23.12.1830","volume":"23","author":"TS Temelkova-Kurktschiev","year":"2000","unstructured":"Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1 c level. Diabetes Care. 2000, 23 (12): 1830-1834. 10.2337\/diacare.23.12.1830.","journal-title":"Diabetes Care"},{"issue":"1","key":"388_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5551\/jat.E515","volume":"15","author":"T Miyazaki","year":"2008","unstructured":"Miyazaki T, Shimada K, Iwama Y, Kume A, Sumiyoshi K, Sato Y, Ohmura H, Watanabe Y, Mokuno H, Daida H: Insulin response to oral glucose load is associated with coronary artery disease in subjects with normal glucose tolerance. J Atheroscler Thromb. 2008, 15 (1): 6-12. 10.5551\/jat.E515.","journal-title":"J Atheroscler Thromb"},{"issue":"13","key":"388_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200003303421301","volume":"342","author":"TW Gress","year":"2000","unstructured":"Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000, 342 (13): 905-912. 10.1056\/NEJM200003303421301.","journal-title":"N Engl J Med"},{"issue":"5","key":"388_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2337\/dc05-2366","volume":"29","author":"EN Taylor","year":"2006","unstructured":"Taylor EN, Hu FB, Curhan GC: Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care. 2006, 29 (5): 1065-1070. 10.2337\/dc05-2366.","journal-title":"Diabetes Care"},{"issue":"4","key":"388_CR6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","volume":"37","author":"JR Sowers","year":"2001","unstructured":"Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001, 37 (4): 1053-1059.","journal-title":"Hypertension"},{"issue":"9557","key":"388_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007, 369 (9557): 201-207. 10.1016\/S0140-6736(07)60108-1.","journal-title":"Lancet"},{"key":"388_CR8","first-page":"671","volume":"16","author":"K Yoshinaga","year":"2000","unstructured":"Yoshinaga K, Iimura O, Abe K, Saruta T, Kurokawa K, Ishii M: A multicenter double-blind comparison study of CS-905 (azelnidipine) with nitrendipine in patients with essential hypertension. Journal of Clinical Therapeutic Medicine. 2000, 16: 671-739.","journal-title":"Journal of Clinical Therapeutic Medicine"},{"issue":"4","key":"388_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1254\/jphs.FP0061139","volume":"103","author":"D Nishiya","year":"2007","unstructured":"Nishiya D, Enomoto S, Omura T, Matsumoto R, Kusuyama T, Izumi Y, Iwao H, Takeuchi K, Yoshiyama M: The long-acting Ca2+-channel blocker azelnidipine prevents left ventricular remodeling after myocardial infarction. J Pharmacol Sci. 2007, 103 (4): 391-397. 10.1254\/jphs.FP0061139.","journal-title":"J Pharmacol Sci"},{"issue":"6","key":"388_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/MAJ.0b013e318065c254","volume":"333","author":"T Nakamura","year":"2007","unstructured":"Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K: Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007, 333 (6): 321-326. 10.1097\/MAJ.0b013e318065c254.","journal-title":"Am J Med Sci"},{"issue":"5","key":"388_CR11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1253\/circj.CJ-11-0141","volume":"75","author":"T Kojima","year":"2011","unstructured":"Kojima T, Miyauchi K, Yokoyama T, Yokoyama K, Kurata T, Suwa S, Kawamura M, Tamura H, Okazaki S, Inoue K: Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). Circ J. 2011, 75 (5): 1071-1079. 10.1253\/circj.CJ-11-0141.","journal-title":"Circ J"},{"issue":"5","key":"388_CR12","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/00005344-200405000-00016","volume":"43","author":"S Yamagishi","year":"2004","unstructured":"Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol. 2004, 43 (5): 724-730. 10.1097\/00005344-200405000-00016.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"388_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/clc.20885","volume":"34","author":"T Nakamura","year":"2011","unstructured":"Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Koide H, Ueda Y, Takeuchi M, Yamagishi S: Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. Clin Cardiol. 2011, 34 (6): 372-377. 10.1002\/clc.20885.","journal-title":"Clin Cardiol"},{"issue":"3","key":"388_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1124\/jpet.106.108894","volume":"319","author":"M Iwai","year":"2006","unstructured":"Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y: Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther. 2006, 319 (3): 1081-1087. 10.1124\/jpet.106.108894.","journal-title":"J Pharmacol Exp Ther"},{"key":"388_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1475-2840-9-82","volume":"9","author":"V Kain","year":"2010","unstructured":"Kain V, Kumar S, Puranik AS, Sitasawad SL: Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage. Cardiovasc Diabetol. 2010, 9: 82-10.1186\/1475-2840-9-82.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"388_CR16","first-page":"3","volume":"32","author":"T Ogihara","year":"2009","unstructured":"Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009, 32 (1): 3-107.","journal-title":"Hypertens Res"},{"key":"388_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s13340-010-0006-7","volume":"1","author":"Y Seino","year":"2010","unstructured":"Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int. 2010, 1: 2-20. 10.1007\/s13340-010-0006-7.","journal-title":"Diabetol Int"},{"issue":"4","key":"388_CR18","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/art.23287","volume":"58","author":"I Colmegna","year":"2008","unstructured":"Colmegna I, Diaz-Borjon A, Fujii H, Schaefer L, Goronzy JJ, Weyand CM: Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis. Arthritis Rheum. 2008, 58 (4): 990-1000. 10.1002\/art.23287.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"388_CR19","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1016\/j.jacc.2004.08.062","volume":"44","author":"PO Bonetti","year":"2004","unstructured":"Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A: Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004, 44 (11): 2137-2141. 10.1016\/j.jacc.2004.08.062.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"388_CR20","doi-asserted-by":"publisher","first-page":"982","DOI":"10.2337\/dc07-1768","volume":"31","author":"AK Gupta","year":"2008","unstructured":"Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR: Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 2008, 31 (5): 982-988. 10.2337\/dc07-1768.","journal-title":"Diabetes Care"},{"issue":"8","key":"388_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/ncpcardio1277","volume":"5","author":"BA Boilson","year":"2008","unstructured":"Boilson BA, Kiernan TJ, Harbuzariu A, Nelson RE, Lerman A, Simari RD: Circulating CD34+ cell subsets in patients with coronary endothelial dysfunction. Nat Clin Pract Cardiovasc Med. 2008, 5 (8): 489-496. 10.1038\/ncpcardio1277.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"6","key":"388_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1291\/hypres.31.1147","volume":"31","author":"S Ogawa","year":"2008","unstructured":"Ogawa S, Mori T, Nako K, Ito S: Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res. 2008, 31 (6): 1147-1155. 10.1291\/hypres.31.1147.","journal-title":"Hypertens Res"},{"key":"388_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1475-2840-8-23","volume":"8","author":"K Node","year":"2009","unstructured":"Node K, Inoue T: Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009, 8: 23-10.1186\/1475-2840-8-23.","journal-title":"Cardiovasc Diabetol"},{"key":"388_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1475-2840-10-24","volume":"10","author":"L Boer-Martins","year":"2011","unstructured":"Boer-Martins L, Figueiredo VN, Demacq C, Martins LC, Consolin-Colombo F, Figueiredo MJ, Cannavan FP, Moreno H: Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients. Cardiovasc Diabetol. 2011, 10: 24-10.1186\/1475-2840-10-24.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"388_CR25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1194\/jlr.R600021-JLR200","volume":"48","author":"C Popa","year":"2007","unstructured":"Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF: The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007, 48 (4): 751-762. 10.1194\/jlr.R600021-JLR200.","journal-title":"J Lipid Res"},{"issue":"5-6","key":"388_CR26","first-page":"215","volume":"31","author":"T Matsui","year":"2005","unstructured":"Matsui T, Yamagishi S, Nakamura K, Kikuchi S, Inoue H: Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells. Drugs Exp Clin Res. 2005, 31 (5-6): 215-219.","journal-title":"Drugs Exp Clin Res"},{"issue":"1","key":"388_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00004872-199715010-00001","volume":"15","author":"P Palatini","year":"1997","unstructured":"Palatini P, Julius S: Heart rate and the cardiovascular risk. J Hypertens. 1997, 15 (1): 3-17. 10.1097\/00004872-199715010-00001.","journal-title":"J Hypertens"},{"issue":"3","key":"388_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1291\/hypres.25.329","volume":"25","author":"K Eguchi","year":"2002","unstructured":"Eguchi K, Kario K, Shimada K: Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res. 2002, 25 (3): 329-333. 10.1291\/hypres.25.329.","journal-title":"Hypertens Res"},{"issue":"11","key":"388_CR29","first-page":"698","volume":"57","author":"T Nada","year":"2007","unstructured":"Nada T, Nomura M, Koshiba K, Kawano T, Mikawa J, Ito S: Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung. 2007, 57 (11): 698-704.","journal-title":"Arzneimittelforschung"},{"issue":"7","key":"388_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1056\/NEJMoa022287","volume":"348","author":"JM Hill","year":"2003","unstructured":"Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003, 348 (7): 593-600. 10.1056\/NEJMoa022287.","journal-title":"N Engl J Med"},{"issue":"3","key":"388_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","volume":"5","author":"DR Sutherland","year":"1996","unstructured":"Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I: The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996, 5 (3): 213-226. 10.1089\/scd.1.1996.5.213.","journal-title":"J Hematother"},{"issue":"2","key":"388_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1161\/01.CIR.104.2.191","volume":"104","author":"F Perticone","year":"2001","unstructured":"Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001, 104 (2): 191-196.","journal-title":"Circulation"},{"issue":"9","key":"388_CR33","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/eurheartj\/ehq010","volume":"31","author":"R Rubinshtein","year":"2010","unstructured":"Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A: Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010, 31 (9): 1142-1148. 10.1093\/eurheartj\/ehq010.","journal-title":"Eur Heart J"},{"issue":"5","key":"388_CR34","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2337\/db08-0063","volume":"57","author":"A Ceriello","year":"2008","unstructured":"Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D: Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008, 57 (5): 1349-1354. 10.2337\/db08-0063.","journal-title":"Diabetes"},{"issue":"7","key":"388_CR35","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1253\/circj.CJ-10-0013","volume":"74","author":"M Hiki","year":"2010","unstructured":"Hiki M, Shimada K, Kiyanagi T, Fukao K, Hirose K, Ohsaka H, Fukushima Y, Kume A, Matsumori R, Sumiyoshi K: Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J. 2010, 74 (7): 1471-1478. 10.1253\/circj.CJ-10-0013.","journal-title":"Circ J"},{"issue":"10","key":"388_CR36","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1161\/01.CIR.0000027569.76671.A8","volume":"106","author":"A Ceriello","year":"2002","unstructured":"Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002, 106 (10): 1211-1218. 10.1161\/01.CIR.0000027569.76671.A8.","journal-title":"Circulation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2840-10-79.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T16:18:07Z","timestamp":1630513087000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/1475-2840-10-79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,10]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1186\/1475-2840-10-79","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,10]]},"assertion":[{"value":"26 June 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"79"}}